Last reviewed · How we verify
HRV PCV-free liquid vaccine
HRV PCV-free liquid vaccine is a Vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Prevention of rotavirus gastroenteritis in infants and young children.
This is a liquid rotavirus vaccine formulation that provides immunization against human rotavirus without pneumococcal conjugate vaccine (PCV) components.
This is a liquid rotavirus vaccine formulation that provides immunization against human rotavirus without pneumococcal conjugate vaccine (PCV) components. Used for Prevention of rotavirus gastroenteritis in infants and young children.
At a glance
| Generic name | HRV PCV-free liquid vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
HRV PCV-free liquid vaccine is a rotavirus vaccine candidate designed to protect against rotavirus infection through active immunization. The 'PCV-free' designation indicates this formulation excludes pneumococcal conjugate vaccine components, distinguishing it from combination vaccine approaches. As a liquid formulation in phase 3 development, it aims to provide convenient administration while maintaining immunogenicity against rotavirus strains.
Approved indications
- Prevention of rotavirus gastroenteritis in infants and young children
Common side effects
- Irritability
- Fever
- Diarrhea
- Vomiting
- Loss of appetite
Key clinical trials
- A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants (PHASE3)
- Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks (PHASE3)
- Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks (PHASE3)
- This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine (PHASE3)
- Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HRV PCV-free liquid vaccine CI brief — competitive landscape report
- HRV PCV-free liquid vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about HRV PCV-free liquid vaccine
What is HRV PCV-free liquid vaccine?
How does HRV PCV-free liquid vaccine work?
What is HRV PCV-free liquid vaccine used for?
Who makes HRV PCV-free liquid vaccine?
What drug class is HRV PCV-free liquid vaccine in?
What development phase is HRV PCV-free liquid vaccine in?
What are the side effects of HRV PCV-free liquid vaccine?
Related
- Drug class: All Vaccine drugs
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of rotavirus gastroenteritis in infants and young children
- Compare: HRV PCV-free liquid vaccine vs similar drugs
- Pricing: HRV PCV-free liquid vaccine cost, discount & access